CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Victoza Liraglutide Diabetes Mellitus, Type 2 Withdrawn
Onivyde Nanoliposomal Irinotecan Cancelled
Venclexta Venetoclax Withdrawn
Cyramza Ramucirumab Cancelled
Praxbind Idarucizumab (Drug Plan Submission) Reversal of dabigatran anticoagulant effects Withdrawn
Avastin Bevacizumab Withdrawn
TBD Cabozantinib Withdrawn
Ikervis cyclosporine keratitis, severe Withdrawn
Breo Ellipta fluticasone furoate/vilanterol COPD Withdrawn
Erbitux Cetuximab Cancelled
Iluvien fluocinolone acetonide Diabetic macular edema (DME) Withdrawn
Atriance Nelarabine Cancelled
TBC ravulizumab Paroxysmal nocturnal hemoglobinuria. Withdrawn
Zytiga (Resubmission) Abiraterone Prostate Cancer Resubmission Withdrawn
TBD Entrectinib Withdrawn
Tecentriq Atezolizumab Withdrawn
TBC etonogestrel Prevention of pregnancy Withdrawn
Kineret anakinra Still's disease Withdrawn
Tysabri natalizumab Multiple Sclerosis, relapsing-remitting Withdrawn
Admelog Insulin lispro Cancelled
Kynmobi apomorphine hydrochloride Parkinson’s Disease Withdrawn
TBD Rituximab Cancelled
Translarna ataluren Cancelled
TBD Trastuzumab Cancelled
Truxima Rituximab Cancelled
Last Updated : July 26, 2024